Erasca (ERAS) Non Operating Income (2020 - 2026)
Erasca's (ERAS) quarterly Non Operating Income came in at $4.5 million in Q1 2026, down 4.14% YoY from $4.7 million in Q1 2025, and up 27.31% on a QoQ basis from $3.5 million in Q4 2025.
Erasca (ERAS) Non Operating Income (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Non Operating Income data on file, last reported at $4.5 million in Q1 2026.
- Quarterly Non Operating Income fell 4.14% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.2 million (down 14.73% YoY) and the FY2025 annual result came in at $16.4 million, down 8.8% from the prior year.
- Non Operating Income grew to $4.5 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $5.9 million in Q3 2024 to a low of $47000.0 in Q1 2022.
- A 5-year average of $3.5 million and a median of $3.9 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 8040.43% — and 2025, when it sank 32.97%.
- Tracing ERAS's Non Operating Income over 5 years: stood at $2.6 million in 2022, then jumped by 59.14% to $4.2 million in 2023, then decreased by 16.57% to $3.5 million in 2024, then rose by 0.92% to $3.5 million in 2025, then gained by 27.31% to $4.5 million in 2026.
- The last three Non Operating Income figures came in at $4.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.60 Mn |
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 4.33 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | 5.87 Mn |
| Jun 30, 2024 | 5.04 Mn |
| Mar 31, 2024 | 3.83 Mn |
| Dec 31, 2023 | 4.17 Mn |
| Sep 30, 2023 | 4.35 Mn |
| Jun 30, 2023 | 4.25 Mn |
| Mar 31, 2023 | 3.83 Mn |
| Dec 31, 2022 | 2.62 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Jun 30, 2022 | 297,000.00 |
| Mar 31, 2022 | 47,000.00 |
| Dec 31, 2021 | -1.35 Mn |
| Sep 30, 2021 | 49,000.00 |